Last reviewed · How we verify
ORE1001
At a glance
| Generic name | ORE1001 |
|---|---|
| Also known as | GL1001 |
| Sponsor | Ore Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ORE1001 CI brief — competitive landscape report
- ORE1001 updates RSS · CI watch RSS
- Ore Pharmaceuticals, Inc. portfolio CI